SANGAMO THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.53 USD | -2.54% |
|
+6.46% | -1.44% |
| 03-22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
| 03-14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Chart calendar Sangamo Therapeutics, Inc.
1fca801a6304f1b1fbc41e63.dxA3ZE0eIFxg2qCXaS9SvZAxbKSbw9klWH94EBncMvY.RXJmUD14SysOm83cDFUa7adDNfHjrJxWIg5JfiuMfLkBRnAULkhxKA7txw~d42431c765d6426d99c92717e1539913
Upcoming events on Sangamo Therapeutics, Inc.
Past events on Sangamo Therapeutics, Inc.
| 30/04/2024 | Q1 2024 Earnings Release (Projected) |
| 13/03/2024 20:30 | Q4 2023 Earnings Call |
| 13/03/2024 12:01 | Q4 2023 Earnings Release |
| 08/02/2024 23:00 | World Symposium - Poster: 145 |
| 08/02/2024 23:00 | World Symposium - Poster: 048 |
| 07/02/2024 23:00 | World Symposium - Poster #145 |
| 10/12/2023 | American Society for Hematology and Exposition Meeting |
| 15/11/2023 09:00 | Jefferies London Healthcare Conference |
| 07/11/2023 | Truist Securities Healthcare Conference |
| 02/11/2023 12:30 | Q3 2023 Earnings Call |
| 01/11/2023 20:01 | Q3 2023 Earnings Release |
| 25/10/2023 17:15 | European Society of Gene Cell Therapy Congress - Abstract No: P212 |
| 25/10/2023 16:00 | European Society of Gene Cell Therapy Congress - Abstract No: P487 |
| 25/10/2023 16:00 | European Society of Gene Cell Therapy Congress - Abstract No: P475 |
| 25/10/2023 16:00 | European Society of Gene and Cell Therapy Conference - Abstract No: P415 |
| 25/10/2023 16:00 | European Society of Gene and Cell Therapy Conference - Abstract No: P503 |
| 24/10/2023 16:00 | European Society of Gene and Cell Therapy Conference - Abstract No: OR09 |
| 27/09/2023 16:00 | Jefferies Cell & Genetic Medicine Summit |
| 06/09/2023 20:45 | Wells Fargo Healthcare Conference |
| 08/08/2023 21:30 | Q2 2023 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 102 63,3 61.9% | 118 124 -4.51% | 111 110 0.62% | 111 111 0.51% | 176 182 -3.3% | 36,9 |
|
EBITDA Million USD | Released Forecast Spread | -101 -146 30.43% | -124 -118 -5.34% | -174 -188 7.34% | -189 -197 4.09% | -104 -247 57.92% | -108 |
|
EBIT Million USD | Released Forecast Spread | -105 -145 27.6% | -130 -115 -12.2% | -183 -196 6.28% | -201 -206 2.18% | -274 -241 -13.8% | -117 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -95,4 -137 30.25% | -121 -107 -13.01% | -178 -191 7% | -192 -198 3.33% | -263 -250 -4.97% | -109 |
|
Net income Million USD | Released Forecast Spread | -95,2 -137 30.65% | -121 -108 -12.47% | -178 -191 6.41% | -192 -199 3.44% | -258 -245 -5.13% | -109 |
|
EPS USD | Released Forecast Spread | -0,85 -1,24 31.31% | -0,90 -0,82 -9.93% | -1,23 -1,33 7.24% | -1,25 -1,30 3.7% | -1,48 -1,38 -6.88% | -0,50 |
| Announcement Date | 28/02/20 | 24/02/21 | 24/02/22 | 22/02/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 28,0 27,4 2.27% | 28,2 27,3 3.46% | 29,4 24,6 19.28% | 26,5 26,8 -1.22% | 27,2 26,9 1.39% | 158 106 49.21% | 6,84 15,3 -55.42% | 9,40 10,4 -9.67% | 2,04 8,11 -74.81% | 6,36 | 7,72 | 7,16 | 17,4 | 12,0 |
|
EBITDA Million USD | Released Forecast Spread | -37,1 -50,9 27.11% | -42,4 -59,5 28.69% | -42,9 -52,5 18.38% | -51,8 -43,5 -19.18% | -52,0 -58,0 10.26% | 80,1 24,8 222.96% | -68,0 -60,2 -12.91% | -56,1 -70,9 20.85% | -59,9 -54,1 -10.79% | -45,5 | -34,5 | -34,6 | 20,3 | |
|
EBIT Million USD | Released Forecast Spread | -39,9 -52,4 23.91% | -45,3 -47,8 5.34% | -45,7 -53,6 14.68% | -54,9 -53,0 -3.6% | -55,4 -59,7 7.27% | 76,6 -29,1 362.86% | -72,2 -58,6 -23.22% | -61,6 -58,0 -6.19% | -62,1 -48,2 -28.73% | -40,3 | -32,0 | -29,1 | -15,3 | -21,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -37,6 -51,1 26.49% | -43,9 -46,8 6.09% | -43,1 -52,7 18.21% | -53,1 -51,6 -3.05% | -51,7 -58,0 10.89% | 21,3 -28,0 176.17% | -121 -56,4 -114.2% | -103 -57,8 -78.06% | -60,6 -47,8 -26.63% | -38,3 | -30,1 | -27,5 | -13,4 | -18,0 |
|
Net income Million USD | Released Forecast Spread | -37,5 -50,9 26.39% | -44,0 -46,8 6.07% | -43,2 -52,5 17.69% | -53,2 -51,5 -3.22% | -52,0 -58,4 10.95% | 21,1 -28,4 174.29% | -115 -57,3 -99.91% | -104 -57,8 -80.26% | -60,3 -47,8 -26.06% | -38,3 | -30,1 | -27,5 | -13,4 | -18,0 |
|
EPS USD | Released Forecast Spread | -0,26 -0,35 25.07% | -0,30 -0,31 4.59% | -0,29 -0,36 18.31% | -0,34 -0,36 4.76% | -0,32 -0,36 10.61% | 0,12 -0,19 162.43% | -0,66 -0,34 -97.01% | -0,59 -0,33 -81.23% | -0,34 -0,26 -32.7% | -0,22 | -0,15 | -0,13 | -0,07 | -0,08 |
| Announcement Date | 24/02/22 | 05/05/22 | 04/08/22 | 03/11/22 | 22/02/23 | 08/05/23 | 08/08/23 | 01/11/23 | 13/03/24 | - | - | - | - | - |
| Today 16:00 | GENMAB A/S: Q1 2024 Earnings Release |
| Today 21:01 | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 05/05/2024 | FRAZIER LIFESCIENCES ACQUISITION CORPORATION: Q1 2024 Earnings Release (Projected) |
| 05/05/2024 | KRYSTAL BIOTECH, INC.: Q1 2024 Earnings Release |
| 05/05/2024 | MERUS N.V.: Q1 2024 Earnings Release (Projected) |
| 05/05/2024 | VAXCYTE, INC.: Q1 2024 Earnings Release (Projected) |
| 05/05/2024 | INHIBRX, INC.: Q1 2024 Earnings Release (Projected) |
| 05/05/2024 | BIONTECH SE: Q1 2024 Earnings Release |
| 06/05/2024 12:00 | BIOCRYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 06/05/2024 21:01 | VERTEX PHARMACEUTICALS INCORPORATED: Q1 2024 Earnings Release |
Past sector events for Sangamo Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- SGMO Stock
- Calendar Sangamo Therapeutics, Inc.
